Agile Therapeutics
AGRX
AGRX was delisted on the 25th of March, 2024.
73 hedge funds and large institutions have $79.5M invested in Agile Therapeutics in 2021 Q1 according to their latest regulatory filings, with 10 funds opening new positions, 17 increasing their positions, 25 reducing their positions, and 13 closing their positions.
421% more call options, than puts
Call options by funds: $1.43M | Put options by funds: $275K
0% more funds holding in top 10
Funds holding in top 10: 1 → 1 (0)
4% less funds holding
Funds holding: 76 → 73 (-3)
23% less first-time investments, than exits
New positions opened: 10 | Existing positions closed: 13
31% less capital invested
Capital invested by funds: $116M → $79.5M (-$36.5M)
32% less repeat investments, than reductions
Existing positions increased: 17 | Existing positions reduced: 25
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
Renaissance Technologies
New York
|
+$1.04M |
| 2 |
Royal Bank of Canada
Toronto,
Ontario, Canada
|
+$438K |
| 3 |
GCP
GSA Capital Partners
London,
United Kingdom
|
+$378K |
| 4 |
Geode Capital Management
Boston,
Massachusetts
|
+$368K |
| 5 |
NIM
Needham Investment Management
New York
|
+$368K |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
Manulife (Manufacturers Life Insurance)
Canada,
Ontario, Canada
|
-$4.5M |
| 2 |
Two Sigma Investments
New York
|
-$1M |
| 3 |
FMBTD
First Midwest Bank Trust Division
Joliet,
Illinois
|
-$859K |
| 4 |
DCM
DG Capital Management
New York
|
-$634K |
| 5 |
Wells Fargo
San Francisco,
California
|
-$378K |
AGRX Hedge Fund Activity: Q1 2021 in Review
73 of the 5,696 institutional investors tracked by Wall St. Rank reported a position in Agile Therapeutics (AGRX) for Q1 2021, worth a combined $79.5M — down 31% from $116M a quarter earlier.
Sellers outnumbered buyers: 13 funds closed out of AGRX and 10 opened new positions — a net loss of 3 holders — while 25 trimmed existing stakes and 17 added.
The largest buyer was Renaissance Technologies, opening a new position worth an estimated $1.04M. The largest seller was Manulife (Manufacturers Life Insurance), exiting entirely with an estimated $4.5M sold.
- 73 institutional investors held Agile Therapeutics (AGRX) as of Q1 2021, down from 76 in Q4 2020.
- Funds reported $79.5M of Agile Therapeutics stock for Q1 2021, down 31% quarter-over-quarter.
- 10 funds opened new Agile Therapeutics positions in Q1 2021 and 13 closed out, a net change of -3 holders.
- The largest Agile Therapeutics buyer in Q1 2021 was Renaissance Technologies, an estimated $1.04M added.
- The largest Agile Therapeutics seller in Q1 2021 was Manulife (Manufacturers Life Insurance), an estimated $4.5M sold.
Based on aggregated 13F filings for Q1 2021.